Login / Signup

A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.

Mari C Vázquez-BorregoVandana GuptaAlejandro Ibáñez-CostaManuel D GaheteEva Venegas-MorenoÁlvaro Toledano-DelgadoDavid A CanoCristóbal Blanco-AcevedoRosa Ortega-SalasMiguel A JapónAna Barrera-MartínAlexandre VasiljevicJason HillShengwen ZhangHeather HalemJusto P. CastañoGerald RaverotMaría A GálvezAlfonso Soto-MorenoMarcelo Paez-PeredaMichael D CullerJusto P CastañoRaúl M Luque
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This study demonstrates that SST3-agonists activate signaling mechanisms that reduce NFPT cell viability and inhibit pituitary tumor growth in experimental models that expresses SST3, suggesting that targeting this receptor could be an efficacious treatment for NFPTs.
Keyphrases
  • growth hormone
  • cancer therapy
  • binding protein
  • drug delivery
  • combination therapy
  • neuroendocrine tumors